BNF 71 FOR FREE DOWNLOAD
71ST EDITION MARCH 2016-SEPT 2016
FOR DOWNLOAD THIS BOOK CLICK HERE ⇙⇊⇊
BNF 71 FOR FREE DOWNLOAD
The British National Formulary (BNF)
provides up-to-date, practical guidance on prescribing, dispensing, and administering medicines.
This essential reference reflects current best practice as well as legal and professional guidelines relating to the uses of medicines.
SOME OF THE SIGNIFICANT CONTENT UPDATES FOR BNF 71 INCLUDE:
➥New safety information, including:
v Very low risk of subacute cutaneous lupus
v Risk of severe bradycardia and
heart block when
v Risk of diabetic ketoacidosis with sodium glucose co-transporter 2
(SGLT2) inhibitors
v Increased reports of eye
irritation since reformulation of latanoprost (Xalatan®)
v Very low risk of subacute cutaneous lupus
v Risk of severe bradycardia and
heart block when
v Risk of diabetic ketoacidosis with sodium glucose co-transporter 2
(SGLT2) inhibitors
v Increased reports of eye
irritation since reformulation of latanoprost (Xalatan®)
FOR DOWNLOAD THIS BOOK CLICK HERE ⇙⇊⇊
BNF 71 FOR FREE DOWNLOAD
MORE DETAILS.......
Bnf 71 (march
2016) has been revised and
revalidated to reflect changes in product availability, emerging safety
concerns and shifts in clinical practice. Access to the latest edition of
the bnf is vital for healthcare professionals, as there are a large number of
updates from one edition to the next...
Bnf 71 (march
2016) has been revised and
revalidated to reflect changes in product availability, emerging safety
concerns and shifts in clinical practice. Access to the latest edition of
the bnf is vital for healthcare professionals, as there are a large number of
updates from one edition to the next...
v Updated advice for further measures to minimise risk of
osteonecrosis of the jaw associated with use of denosumab and intravenous
bisphosphonates
v Inclusion of monitoring recommendations for risks of
cardiac failure with crizotinib
updates to immunisation schedule (summer 2015): meningococcal group b vaccine,
meningococcal groups a, c, w135 and y vaccine, and influenza vaccine added
addition of new preparations including otezla® (apremilast),
kengrexal® (cangrelor), velphoro® (sucroferric oxyhydroxide), and more
v Significant dose changes including avanafil, colistimethate
sodium (promixin®), oseltamivir, and more
v Updated advice for further measures to minimise risk of
osteonecrosis of the jaw associated with use of denosumab and intravenous
bisphosphonates
v Updated safety information on risk factors for uterine
perforation associated with the use of intra-uterine contraception (intra-uterine
contraceptive devices (copper) and levonorgestrel)
v Inclusion of monitoring recommendations for risks of
cardiac failure with crizotinib
updates to immunisation schedule (summer 2015): meningococcal group b vaccine,
meningococcal groups a, c, w135 and y vaccine, and influenza vaccine added
addition of new preparations including otezla® (apremilast),
kengrexal® (cangrelor), velphoro® (sucroferric oxyhydroxide), and more
v Significant dose changes including avanafil, colistimethate
sodium (promixin®), oseltamivir, and more
Comments
Post a Comment